In clinical settings, both MO-MDSC (CD33+CD14+CD15–HLA-DRlo) and PMN-MDSC (CD33+CD14–CD15+HLA-DR–) had pro-tumor effects, and the ratio of these two subsets was distinct among different tumor types and therefore potentially impacted treatment strategies [44]. This evidence concerns the gene CD33 and neoplasm.